Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
BAY1003803 · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| BAY1003803 0.1% lipophilic cream | EXPERIMENTAL | BAY1003803 0.1% lipophilic cream (on plaque and healthy skin) |
| BAY1003803 0.1% ointment | EXPERIMENTAL | BAY1003803 0.1% ointment (on plaque and healthy skin) |
| BAY1003803 0.01% lipophilic cream | EXPERIMENTAL | BAY1003803 0.01% lipophilic cream (on plaque and healthy skin) |
| BAY1003803 0.01% ointment | EXPERIMENTAL | BAY1003803 0.01% ointment (on plaque and healthy skin) |
| Clobetasol propionate | ACTIVE_COMPARATOR | Clobetasol propionate ointment 0.05 % (on plaque and healthy skin) |
| Betamethasone/calcipotriene | ACTIVE_COMPARATOR | Betamethasone/calcipotriene ointment 0.05 %/0.005% (on healthy skin) |
| Name | Type | Description |
|---|---|---|
| BAY1003803 | DRUG | Simultaneous application of 10μl on psoriasis plaque and on healthy skin for 4 weeks and evaluation of pharmacodynamic effect |
| Clobetasol propionate | DRUG | Simultaneous application of 10μl on psoriasis plaque and on healthy skin for 4 weeks and evaluation of pharmacodynamic effect |
| Betamethasone/calcipotriene | DRUG | Simultaneous application of 10μl on healthy skin for 4 weeks and evaluation of pharmacodynamic effect |
Inclusion Criteria: * Male and female (non-childbearing potential) volunteer with stable plaque-type psoriasis, but otherwise healthy * Age: 18-64 years Exclusion Criteria: * Severe disease within the last 4 weeks prior to the first study drug administration as determined by the investigator * An...
BAY1003803 is an investigational small molecule being developed for the treatment of psoriasis, a chronic skin condition. It is currently in Phase 1 clinical development and has been studied in a completed clinical trial in Germany.
BAY1003803 is being developed by Bayer AG, a multinational pharmaceutical company. Bayer's stock is traded on the OTC market under the ticker symbol BAYRY.
BAY1003803 is in Phase 1 clinical development. It is an investigational drug and has not yet been approved by regulatory authorities. One Phase 1 trial has been completed, and the drug is not currently in any active clinical trials.
BAY1003803 has been studied in one completed Phase 1 clinical trial with the identifier NCT02940002. The trial, titled 'BAY1003803 Formulation Comparison in Open Psoriasis Plaque Test,' enrolled 23 participants with psoriasis in Germany.
BAY1003803 is the only name provided for this drug. No alternative names have been reported. It is a small molecule being developed by Bayer AG for the treatment of psoriasis.